Malignant Pleural Effusion (Respiratory) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Pleural Effusion – Drugs In Development, 2021, provides an overview of the Malignant Pleural Effusion (Respiratory) pipeline landscape.

Malignant pleural effusion is a condition in which cancer causes an abnormal amount of fluid to collect between the thin layers of tissue (pleura) lining the outside of the lung and the wall of the chest cavity. Lung cancer, breast cancer, lymphoma, and leukemia cause most malignant pleural effusions.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Pleural Effusion – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Malignant Pleural Effusion (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Pleural Effusion (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Malignant Pleural Effusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 3, 3 and 2 respectively.

Malignant Pleural Effusion (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Pleural Effusion (Respiratory).

– The pipeline guide reviews pipeline therapeutics for Malignant Pleural Effusion (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Malignant Pleural Effusion (Respiratory) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Malignant Pleural Effusion (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Pleural Effusion (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Malignant Pleural Effusion (Respiratory).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Malignant Pleural Effusion (Respiratory) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Amgen Inc

BioSyngen Pte Ltd

Clover Biopharmaceuticals

Genelux Corp

Gongwin Biopharm Holdings Co Ltd

Hubei Soundny Bio-Tech Co Ltd

Jiangsu Simcere Pharmaceutical Co Ltd

Lipac Oncology LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Malignant Pleural Effusion - Overview

Malignant Pleural Effusion - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Malignant Pleural Effusion - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Malignant Pleural Effusion - Companies Involved in Therapeutics Development

Amgen Inc

BioSyngen Pte Ltd

Clover Biopharmaceuticals

Genelux Corp

Gongwin Biopharm Holdings Co Ltd

Hubei Soundny Bio-Tech Co Ltd

Jiangsu Simcere Pharmaceutical Co Ltd

Lipac Oncology LLC

Malignant Pleural Effusion - Drug Profiles

BSG-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

endostatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methotrexate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olvimulogene nanivacirepvec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

paclitaxel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PTS-500 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCB-313 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

talimogene laherparepvec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Malignant Pleural Effusion - Dormant Projects

Malignant Pleural Effusion - Product Development Milestones

Featured News & Press Releases

Jan 10, 2020: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Malignant Pleural Effusions (MPE)

Nov 21, 2019: Clover Biopharmaceuticals doses first patient in Phase I study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)

Sep 29, 2019: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Malignant Ascites

May 12, 2015: Genelux to Present Posters Supporting Lead Oncolytic Viral Therapy GL-ONC1 at ASCO Annual Meeting 2015

Jun 15, 2013: Genelux Presents Abstracts at the 7th International Meeting on Replicating Oncolytic Virus Therapeutics in Quebec

May 30, 2013: Genelux To Present Abstracts For Clinical Trials Of Oncolytic Viral Therapy GL-ONC1 At 2013 ASCO Annual Meeting

Feb 06, 2013: Genelux Announces Treatment Of First Patient In Phase I Trial With GL-ONC1 At Memorial Sloan Kettering Cancer Center

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Malignant Pleural Effusion, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Malignant Pleural Effusion – Pipeline by Amgen Inc, 2021

Malignant Pleural Effusion – Pipeline by BioSyngen Pte Ltd, 2021

Malignant Pleural Effusion – Pipeline by Clover Biopharmaceuticals, 2021

Malignant Pleural Effusion – Pipeline by Genelux Corp, 2021

Malignant Pleural Effusion – Pipeline by Gongwin Biopharm Holdings Co Ltd, 2021

Malignant Pleural Effusion – Pipeline by Hubei Soundny Bio-Tech Co Ltd, 2021

Malignant Pleural Effusion – Pipeline by Jiangsu Simcere Pharmaceutical Co Ltd, 2021

Malignant Pleural Effusion – Pipeline by Lipac Oncology LLC, 2021

Malignant Pleural Effusion – Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development for Malignant Pleural Effusion, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports